Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat-containing protein 35 (WDR35) is a core component of the intraflagellar transport A (IFT-A) complex, which is essential for the assembly and maintenance of primary cilia by mediating retrograde transport of proteins and membrane cargo from the ciliary tip to the base[1][3][4][6]. As a member of the WD repeat protein family, it facilitates multiprotein complex formation and has roles in cell cycle progression, apoptosis, and gene regulation[1][5][7]. WDR35 is crucial for proper Sonic Hedgehog signaling and developmental processes, especially during embryogenesis. Mutations in WDR35 disrupt ciliary function, manifesting as a spectrum of skeletal and multisystem ciliopathies, most notably cranioectodermal dysplasia (Sensenbrenner syndrome) and short-rib thoracic dysplasia[3][5]. No approved drugs specifically target WDR35; its dysfunction emerges primarily as a genetic disease mechanism rather than a current therapeutic target[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat-containing protein 35 (WDR35).